May 21, 2013
Boston Scientific (NYSE: BSX) makes cardiology products such as drug-eluting stents and pacemakers, which each respectively accounting for 21% and 16% of total revenues. Drug-coated stents are used to prop up coronary arteries to help prevent heart attacks, but their effectiveness have been questioned after they were linked to a risk of blood clots, as well as competition from Abbott's stent Xience.[1]
Boston Scientific also makes Endosurgery and Neuromodulation products. The Endosurgery group includes esophageal, gastric, and duodenal intervention products; colorectal, pancreatico-biliary, and pulmonary intervention devices; and products for urinary tract intervention and bladder disease, prostate intervention, pelvic floor reconstruction and urinary incontinence, gynecology, and oncology. The Neuromodulation group comprises Precision Spinal Cord Stimulation system for the treatment of chronic pain of the lower back and legs, and HiResolution 90K Cochlear Implant system to restore hearing to the profoundly deaf. Boston Scientific Corporation markets its products through direct sales force, and a network of distributors and dealers.
(Read more at Wikinvest
) - Corporate Overview
- Business and Financial Metrics
- Business Segments[3]
- Cardiac Rhythm Management
- Electrophysiology
- Interventional Cardiology
- Peripheral Interventions
- Neurovascular
- Endoscopy
- Urology/Women’s Health
- Neuromodulation
- Market Penetration
- Clinical trials
- Product diversification and innovation
- Quality control
- Competition
- References
